Articles científics publicats pels investigadors del Barcelonaβeta Brain Research Center (BBRC), relacionats amb la malaltia d'Alzheimer, la neuroimatge, la memòria i les malalties neurodegeneratives, entre altres camps.
Kuhn E, Klinger HM, Amariglio RE, Wagner M, Jessen F, Düzel E, Heneka MT, Chételat G, Rentz DM, Sperling RA, Ebenau JL, Butterbrod E, Van Der Flier WM, Sikkes SAM, Teunnissen CE, Van Harten AC, Van De Giessen EM, Rami L, Tort A, Sánchez Benavides G, Gifford KA, Van Hulle C, Buckley RF.
Introduction: Specific features of subjective cognitive decline (SCD-plus) have been proposed to indicate an increased risk of preclinical Alzheimer's disease (AD). However, few studies have examined...
Anastasi F, Fernández-Lebrero A, Ashton NJ, Ortiz-Romero P, Torres-Torronteras J, González-Escalante A, Milà-Alomà M, Contador J, García-Escobar G, Manero-Borràs RM, Navalpotro-Gómez I, Jiménez-Moyano E, Sahajan A, Hao Q, Zhang B, Jeromin A, Le Bastard N, Nadal A, Mousavi T, Kollmorgen G, Carboni M, Grau-Rivera O, Zetterberg H, Del Campo M, Blennow K, Puig-Pijoan A, Suárez-Calvet M.
Introduction: Blood-based biomarkers for Alzheimer's disease (AD) have been widely studied, but direct comparisons of several biomarkers in clinical settings remain limited.
Methods: In this cross...
Cacciaglia R, Falcón C, Benavides GS, Brugulat-Serrat A, Alomà MM, Calvet MS, Molinuevo JL, Fauria K, Minguillón C, Kollmorgen G, Quijano-Rubio C, Blennow K, Zetterberg H, Lorenzini L, Wink AM, Ingala S, Barkhof F, Ritchie CW, Gispert JD
Introduction: Identifying the link between early Alzheimer's disease (AD) pathological changes and neurodegeneration in asymptomatic individuals may lead to the discovery of preventive strategies. We...
Bolsewig K, Willemse EAJ, Sánchez-Juan P, Rábano A, Martínez M, Doecke JD, Bellomo G, Vermunt L, Alcolea D, Halbgebauer S, In 't Veld S, Mattsson-Carlgren N, Veverova K, Fowler CJ, Boonkamp L, Koel-Simmelink M, Hussainali Z, Ruiters DN, Gaetani L, Toja A, Fortea J, Pijnenburg Y, Lemstra AW, van der Flier WM, Hort J, Otto M, Hansson O, Parnetti L, Masters CL, Lleó A, Teunissen CE, Del Campo Milán M.
DOPA Decarboxylase (DDC) has been proposed as a cerebrospinal fluid (CSF) biomarker with increased concentrations in Lewy body disorders (LBDs) and highest levels in patients receiving dopaminergic...
Jin J, Chen J, Cavaillès C, Yaffe K, Winer J, Stankeviciute L, Lucey BP, Zhou X, Gao S, Peng D, Leng Y.
Introduction: Sleep disturbances are associated with Alzheimer's disease (AD) and Alzheimer's disease and related dementias (ADRD), but the relationship between sleep architecture, particularly rapid...
Genius P, Calle ML, Rodríguez-Fernández B, Minguillon C, Cacciaglia R, Garrido-Martin D, Esteller M, Navarro A, Gispert JD, Vilor-Tejedor N.
Introduction: Traditional multivariate methods for neuroimaging studies overlook the interdependent relationship between brain features. This study addresses this gap by analyzing relative brain...
Biel D, Suárez-Calvet M, Dewenter A, Steward A, Roemer SN, Dehsarvi A, Zhu Z, Pescoller J, Frontzkowski L, Kreuzer A, Haass C, Schöll M, Brendel M, Franzmeie
In Alzheimer's disease (AD), Aβ triggers p-tau secretion, which drives tau aggregation. Therefore, it is critical to characterize modulators of Aβ-related p-tau increases which may alter AD...
Aye S, Johansson G, Hock C, Lannfelt L, Sims JR, Blennow K, Frederiksen KS, Graff C, Molinuevo JL, Scheltens P, Palmqvist S, Schöll M, Wimo A, Kivipelto M, Handels R, Frölich L, Zilka N, Tolar M, Johannsen P, Jönsson L, Winblad B
The advancement of disease-modifying treatments (DMTs) for Alzheimer's disease (AD), along with the approval of three amyloid-targeting therapies in the US and several other countries, represents a...
Argiris G, Akinci M, Peña-Gómez C, Palpatzis E, Garcia-Prat M, Shekari M, Blennow K, Zetterberg H, Kollmorgen G, Quijano-Rubio C, Ashton NJ, Karikari TK, Brinkmalm-Westman A, Lantero-Rodriguez J, Fauria K, Sánchez-Benavides G, Grau-Rivera O, Suárez-Calvet M, Arenaza-Urquijo EM.
Background: Cerebrospinal fluid (CSF) biomarkers of synaptic dysfunction, neuroinflammation, and glial response, complementing Alzheimer's disease (AD) core biomarkers, have improved the...
Canals-Gispert L, Cañas-Martínez A, Huesa G, Suárez-Calvet Alomà M, Milà-Alomà M, Arenaza-Urquijo E, Cirillo D, Dimech AS, Iulita MF, Martinkova JN, Tartaglia MC, Quevenco FC, Chadha AS, Sánchez-Benavides G, Minguillón C, Ferretti MT, Fauria K, Brugulat-Serrat A
Background: Although there is growing evidence of the association between gender and early diagnosis of preclinical Alzheimer's disease, little attention has been given to the enrolment ratio of men...